TORNTPHARM Q4 FY26 Guidance vs Delivery (TORNTPHARM Management Mirror)

India Business Outlook & Field Force

Management continues to expect the India business to outperform market growth, projecting higher YoY organic growth for the base business next year absent geopolitical shocks, as stated in the Mar'26 Qtr. The target to expand the medical representative count to 7,500 by Mar'27 was maintained from the Dec'25 Qtr, scaling from the 7,000 target outlined in the Sep'25 Qtr, with no further additions planned post-merger. Management anticipates INR 200 to INR 250 crores in semaglutide sales, with margins improving over six months following a price cut to INR 109, while Resmiterom is projected to launch in 12 to 18 months. [Status: Reaffirmed]